Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

50%

Ph phase_1

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

2(50.0%)

Phase 2Efficacy & side effects

2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Other(1)

Detailed Status

Completed2

unknown1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (50.0%)

Phase 22 (50.0%)

Trials by Status

completed250%

unknown125%

withdrawn125%

Recent Activity

0 active trials

Showing 4 of 4

unknownphase_2

A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

NCT00423306

withdrawnphase_1

Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma

NCT01139359

completedphase_1

Study of Oral Darinaparsin in Patients With Advanced Solid Tumors

NCT01139346

completedphase_2

Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

NCT00421213

Clinical Trials (4)

Showing 4 of 4 trials

NCT00423306Phase 2

A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

Unknown

NCT01139359Phase 1

Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma

Withdrawn

NCT01139346Phase 1

Study of Oral Darinaparsin in Patients With Advanced Solid Tumors

Completed

NCT00421213Phase 2

Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4